DiaMedica Therapeutics Inc. Common Stock (DMAC) Stock Price

DMACStock

$6.74+6.71%52W

Market Cap$363.46M

P/E—

PEG Ratio—

Div yield—

Beta0.96

DMAC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-35.61%

Price vs S&P 500 (4W)-4.86%

VGM Score51.83

Book Value / Share (Quarterly)$0.88

P/TBV (Annual)42.56x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.58

Price vs S&P 500 (YTD)-30.05%

EPS (TTM)$-0.71

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-0.71

EPS (Annual)$-0.70

ROI (Annual)-58.38%

Net Profit Margin (5Y Avg)-11188.60%

Cash / Share (Quarterly)$0.95

ROA (Last FY)-53.39%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-46.04%

Cash Flow / Share (Annual)$-0.54

P/B Ratio7.64x

P/B Ratio (Quarterly)7.72x

Net Income / Employee (Annual)$-936,200

Net Interest Coverage (TTM)-143.97x

ROA (TTM)-69.18%

EPS Incl Extra (Annual)$-0.70

Current Ratio (Annual)11.81x

Quick Ratio (Quarterly)8.98x

3-Month Avg Trading Volume0.19M

52-Week Price Return6.71%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.38

P/S Ratio (Annual)721.53x

Asset Turnover (Annual)0.03x

52-Week High$10.42

Operating Margin (5Y Avg)-11740.00%

EPS Excl Extra (Annual)$-0.70

CapEx CAGR (5Y)-3.17%

Tangible BV CAGR (5Y)-14.37%

26-Week Price Return-24.36%

Quick Ratio (Annual)11.72x

13-Week Price Return13.00%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.11x

Enterprise Value$355.91M

Book Value / Share Growth (5Y)-5.53%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1130.80%

Cash / Share (Annual)$1.11

3-Month Return Std Dev49.39%

Net Income / Employee (TTM)$-1,002,900

ROE (Last FY)-58.39%

Net Interest Coverage (Annual)-49.10x

EPS Basic Excl Extra (Annual)$-0.70

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.71

Receivables Turnover (Annual)1.16x

ROI (TTM)-77.06%

Pretax Margin (5Y Avg)-11149.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.38

Price vs S&P 500 (52W)-11.60%

Year-to-Date Return-18.09%

5-Day Price Return-1.36%

EPS Normalized (Annual)$-0.70

ROA (5Y Avg)-42.30%

Net Profit Margin (Annual)-1146.80%

Month-to-Date Return2.84%

Cash Flow / Share (TTM)$-0.61

EBITD / Share (Annual)$-0.73

Operating Margin (Annual)-1352.20%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-46.03%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-0.71

P/TBV (Quarterly)42.56x

P/B Ratio (Annual)7.39x

Book Value / Share (Annual)$1.04

Price vs S&P 500 (13W)10.20%

Beta0.96x

Revenue / Share (TTM)$0.00

ROE (TTM)-77.09%

52-Week Low$5.14

mGradeC

vgmGradeC

DMAC Earnings Surprise History

Q2 25-0.18est. -0.19

Q3 25-0.17est. -0.16

Q4 25-0.17est. -0.18

Q1 26-0.19est. -0.18

Q2 26-0.19est. -0.20

DMAC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.09

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
DMACDiaMedica Therapeutics Inc. Common Stock	—	—	C	$6.74
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About DiaMedica Therapeutics Inc. Common Stock

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing therapies for ischemic diseases and acute pancreatitis. Its lead candidate, DM199, a recombinant human enzyme, is in clinical trials for acute ischemic stroke and preeclampsia. The company also develops DM300, a protease inhibitor being evaluated for severe acute pancreatitis.